Pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements Regulations, 2018, Orchid Pharma has informed that it enclosed Monitoring Agency Report issued by Care Ratings, Monitoring Agency, for the quarter ended June 30, 2023 in respect of utilization of proceeds raised through Qualified Institutional Placement.
The above information is a part of company’s filings submitted to BSE.
